Ranked #2,833 of 8,699 institutional investors
Vivo Capital, LLC
Palo Alto, CA
$749M
US stock portfolio at live prices · today −$16.5M (−2.16%)
Live prices, last trade 10:47 AM ET
- Value at quarter end (Q3 2026)
- $909M
- Change from Q2 2026
- −$186.4M (−17.02%)
- Positions
- 47 · 6 new, 4 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: none$36.8M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPRAX 11.1%TRVI 7.61%ERAS 7.31%ANRO 4.62%KRSA 4.41%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | 271,116 | $83.4M | 11.1% | Unchanged |
| TRVI Trevi Therapeutics, Inc. | 4,229,683 | $57.0M | 7.61% | Reduced −17% |
| ERAS Erasca, Inc. | 4,020,619 | $54.7M | 7.31% | Reduced −3% |
| ANRO Alto Neuroscience Inc | 1,359,915 | $34.6M | 4.62% | Added +12% |
| KRSA Korsana Biosciences, Inc. | 877,020 | $33.0M | 4.41% | New |
| LBRX LB Pharmaceuticals Inc | 800,000 | $31.5M | 4.20% | Unchanged |
| TNGX Tango Therapeutics, Inc. | 1,379,769 | $30.8M | 4.11% | Unchanged |
| ABVX ABIVAX Société Anonyme | 414,899 | $28.0M | 3.74% | Unchanged |
| CRVS Corvus Pharmaceuticals, Inc. | 2,805,816 | $27.2M | 3.64% | Unchanged |
| ACRS Aclaris Therapeutics, Inc. | 6,694,637 | $23.3M | 3.12% | Unchanged |
| BLSM BlossomHill Therapeutics, Inc. | 1,493,740 | $21.9M | 2.93% | New |
| CAMP Camp4 Therapeutics Corp | 5,584,111 | $21.6M | 2.88% | Added +31% |
| AVBP ArriVent BioPharma, Inc. | 1,787,104 | $19.6M | 2.63% | Added +6% |
| SABS SAB Biotherapeutics, Inc. | 6,915,011 | $18.6M | 2.49% | Reduced −5% |
| DBVT DBV Technologies S.A. | 1,844,758 | $16.9M | 2.26% | Unchanged |
| ANTX AN2 Therapeutics, Inc. | 3,153,640 | $16.6M | 2.22% | Unchanged |
| QUIT Achieve Life Sciences, Inc. | 2,751,032 | $15.8M | 2.11% | Unchanged |
| MLTX MoonLake Immunotherapeutics | 1,400,000 | $15.4M | 2.06% | Unchanged |
| DSGN Design Therapeutics, Inc. | 1,612,903 | $15.0M | 2.00% | Unchanged |
| VOR Vor Biopharma Inc. | 550,358 | $10.7M | 1.44% | New |
| ODTX Odyssey Therapeutics, Inc. | 575,000 | $9.9M | 1.33% | Unchanged |
| NERV Minerva Neurosciences, Inc. | 4,322,747 | $9.0M | 1.20% | Unchanged |
| PEPG PepGen Inc. | 2,325,000 | $8.9M | 1.19% | Unchanged |
| DRUG Bright Minds Biosciences Inc. | 417,879 | $8.8M | 1.17% | Reduced −25% |
| DYN Dyne Therapeutics, Inc. | 514,402 | $8.2M | 1.10% | Reduced −67% |
| AURA Aura Biosciences, Inc. | 1,166,667 | $8.0M | 1.07% | Unchanged |
| EPRX Eupraxia Pharmaceuticals Inc. | 1,350,000 | $8.0M | 1.06% | Unchanged |
| SRZN Surrozen, Inc. | 260,000 | $7.7M | 1.03% | Unchanged |
| FTH Faeth Therapeutics, Inc. | 844,576 | $7.3M | 0.97% | Added +17% |
| ORIC ORIC Pharmaceuticals, Inc. | 924,392 | $7.1M | 0.94% | Reduced −50% |
| MNPR Monopar Therapeutics Inc. | 90,500 | $6.2M | 0.83% | Unchanged |
| EDIT Editas Medicine, Inc. | 3,555,250 | $6.2M | 0.82% | Unchanged |
| OKUR OnKure Therapeutics, Inc. | 1,927,710 | $5.3M | 0.71% | Unchanged |
| OLMA Olema Oncology, Inc. | 671,843 | $4.8M | 0.64% | Unchanged |
| MSLE Satellos Bioscience Inc. | 813,666 | $4.6M | 0.62% | Unchanged |
| ATTO Attovia Therapeutics, Inc. | 300,000 | $4.5M | 0.60% | New |
| VALN Valneva SE | 763,199 | $4.0M | 0.54% | Unchanged |
| ADRX ADARx Pharmaceuticals, Inc. | 255,158 | $3.6M | 0.48% | New |
| TENX Tenax Therapeutics, Inc. | 2,500,000 | $3.3M | 0.44% | Unchanged |
| SERA Sera Prognostics, Inc. | 1,650,440 | $3.0M | 0.40% | Unchanged |
| CMPX Compass Therapeutics, Inc. | 3,423,547 | $2.4M | 0.32% | Reduced −56% |
| AVTX Avalo Therapeutics, Inc. | 275,000 | $1.9M | 0.25% | Unchanged |
| TIL Instil Bio, Inc. | 292,743 | $1.6M | 0.21% | Unchanged |
| CUE Cue Biopharma, Inc. | 280,057 | $1.2M | 0.16% | New |
| BOLT Bolt Biotherapeutics, Inc. | 72,414 | $359K | <0.1% | Unchanged |
| KTTA Pasithea Therapeutics Corp. | 372,796 | $179K | <0.1% | Reduced −20% |
| DTIL Precision BioSciences, Inc. | 4,675 | $34K | <0.1% | Unchanged |